Canaccord Genuity raises AtriCure stock price target to $64 on strong Q3 results
PositiveFinancial Markets

Canaccord Genuity has raised its price target for AtriCure's stock to $64 following impressive third-quarter results. This adjustment reflects confidence in AtriCure's performance and growth potential, which is significant for investors looking for promising opportunities in the healthcare sector. AtriCure's strong results indicate a robust demand for its innovative solutions, making this news particularly relevant for stakeholders and market watchers.
— Curated by the World Pulse Now AI Editorial System











